During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...

Janus kinase (JAK) inhibitors are associated with decreased mortality and fewer serious adverse events among adults hospitalized with COVID-19.

Discover a study uncovering how JAK inhibitors protect against autoimmune diabetes triggered by cancer immunotherapy.

A new study offers insights into the relative efficacy of various treatments for alopecia areata (AA), suggesting that ...

Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and ...

Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

What are Janus kinase inhibitors? Janus kinase inhibitors (including tofacitinib) are a class of medications which reduce inflammation in the body. Tofacitinib is currently being used in autoimmune ...

Researchers are working to launch a first-in-human clinical trial to test the approach in patients with cancer who develop diabetes after immunotherapy.

New Janus kinase inhibitors may benefit more patients with MF given their reduced myelosuppression, a study found.

For example, just a couple of weeks ago, the third JAK to market, upadacitinib, recently got approval from the FDA for use in giant cell arteritis, and so in addition to the rheumatoid arthritis ...

VIDEO: Addressing inadequate response to JAK inhibitorsEditor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of ...